Cellectis Announces Two Oral Presentations and One Poster Presentation at the 2017 ASH Annual Meeting NEW YORK--(BUSINESS WIRE)

Announces Two Oral Presentations and One Poster Presentation at the 2017

NEW YORK--(BUSINESS WIRE)--November 1, 2017--Regulatory News:

Cellectis (Paris:ALCLS) (NASDAQ:CLLS) (Alternext: ALCLS - Nasdaq:

CLLS), a clinical-stage biopharmaceutical company focused on

developing immunotherapies based on gene-edited allogeneic CAR T-cells

(UCART), announced today that abstracts regarding the Company's

allogeneic, off-the-shelf, CAR T product candidates have been accepted

for presentation at the 59th American Society of Hematology (ASH) Annual

Meeting and Exposition. The meeting will be held from December 9 to 12,

2017 in Atlanta, GA.

UCARTCS1 product candidate targeting Multiple Myeloma

502. Universal SLAMF7-Specific CAR T-Cells As Treatment for Multiple

Abstract: https://ash.confex.com/ash/2017/webprogram/Paper106073.html

Name: 652. Myeloma: Pathophysiology and Pre-Clinical Studies, excluding

Therapy: Novel Immunotherapeutic Strategies in Multiple Myeloma Session

December 10, 2017 at 5:15 PM

Location: Bldg B, Lvl 3, B308-B309

(Georgia World Congress Center)

Rohit Mathur1, Zheng Zhang1, Jin He1,

Roman Galetto2, Agn s Gouble2, Isabelle

Chion-Sotinel2, St phanie Filipe2, Annabelle

Gariboldi2, Tanooha Veeramachaneni1, Elisabet E.

Manasanch1, Sheeba K. Thomas1, Hans C. Lee1,

Krina K. Patel1, Donna M. Weber1, R. Eric Davis1,

Robert Z. Orlowski1, Julianne Smith3, Jing Yang1,

and Sattva S. Neelapu1

1Department of Lymphoma and Myeloma, The University

of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd., Houston, TX

2Cellectis SA, 8 rue de la croix

Jarry, 75013 Paris, France

430 East 29th Street, 10016 New York, NY, USA

UCART22 product candidate targeting B-Acute Lymphoblastic Leukemia

808. Pre-clinical Activity of Allogeneic Anti-CD22 CAR T-Cells for

the Treatment of B-cell Acute Lymphoblastic Leukemia

Abstract: https://ash.confex.com/ash/2017/webprogram/Paper105595.html

Name: 614. Acute Lymphoblastic Leukemia: Therapy, excluding

Transplantation: CAR-T Cell Immunotherapy

Monday, December 11,

Location: Bldg C, Lvl 1, Hall C4 (Georgia World

Julia Wells PhD1, Tianyu Cai, PhD1,

C cile Schiffer-Manniou PhD2, St phanie Filipe, PhD2,

Agn s Gouble, PhD2, Roman Galetto, PhD2,

Nitin Jain MD1, Elias Jabbour MD1, Julianne

SmithPhD3 and Marina Konopleva, MD, PhD1

1Department of Leukemia, The University of Texas MD

Anderson Cancer Center, Houston, TX

3Cellectis Inc, New York,

Poster Presentation:

UCART123 product candidate targeting Blastic Plasmacytoid Dendritic

2625. Pre-Clinical Studies of Allogeneic Anti-CD123 CAR T-Cells for

the Therapy of Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)

Abstract: https://ash.confex.com/ash/2017/webprogram/Paper105789.html

Name: 616. Acute Myeloid Leukemia: Novel Therapy, excluding

Transplantation: Poster II

Sunday, December 10, 2017 from 6:00 PM

Location: Bldg A, Lvl 1, Hall A2 (Georgia World

Tianyu Cai1, Roman Galetto2, Agn s Gouble2,

Julianne Smith3, Antonio Cavazos1, Lina Han1,

Qi Zhang1, Vinitha Kuruvilla1, Sergej Konoplev4,

Sattva S. Neelapu5, Andrew A. Lane6, Monica Guzman7,

Hagop Kantarjian1, Naveen Pemmaraju1, Marina

1Department of Leukemia, The University of Texas MD

Anderson Cancer Center, Houston, TX

3Cellectis Inc, New York,

4Department of Hematopathology, The

University of MD Anderson Cancer Center, Houston, TX

of Lymphoma and Myeloma, The University of MD Anderson Cancer Center,

6Dana-Farber Cancer Institute,

7Department of Medicine, Weill

Cornell Medical College, New York, NY

Cellectis is a clinical-stage biopharmaceutical company focused on

developing a new generation of cancer immunotherapies based on

gene-edited T-cells (UCART). By capitalizing on its 17 years of

expertise in gene editing - built on its flagship TALEN technology and

pioneering electroporation system PulseAgile - Cellectis uses the power

of the immune system to target and eradicate cancer cells.

Using its life-science-focused, pioneering genome engineering

technologies, Cellectis' goal is to create innovative products in

multiple fields and with various target markets.

on the Nasdaq market (ticker: CLLS) and on the NYSE Alternext market

(ticker: ALCLS). To find out more about us, visit our website: www.cellectis.com

Talking about gene editing? We do it. TALEN is a registered trademark

owned by the Cellectis Group.

This press release contains "forward-looking" statements that are based

on our management's current expectations and assumptions and on

information currently available to management. Forward-looking

statements involve known and unknown risks, uncertainties and other

factors that may cause our actual results, performance or achievements

to be materially different from any future results, performance or

achievements expressed or implied by the forward-looking statements.

Further information on the risks factors that may affect company

business and financial performance, is included in filings Cellectis

makes with the Security Exchange Commission from time to time and its

financial reports. Except as required by law, we assume no obligation to

update these forward-looking statements publicly, or to update the

reasons actual results could differ materially from those anticipated in

the forward-looking statements, even if new information becomes

available in the future.

For further information, please contact:

Jennifer Moore, 917-580-1088